Abstract
Three different approaches were employed to assess various markers associated with sex differences in responses to methamphetamine (MA). Bioassay measures reveal that MA treatment results in significantly greater reductions in body weight and increases in body temperature in male mice. Protein and mRNA determinations show significant increases in Bcl-2 and PAI-1 in male mice, while females show significant increases in GFAP and decreases in IGF-1R following treatment with MA. In mice with a heterozygous mutation of their dopamine transporter (+/- DAT), only female mice show significant differences in dopamine transporter binding and mRNA and associated reductions in striatal dopamine content along with increases in MA-evoked striatal dopamine output. The identification of these sex-dependent differences in markers provides a foundation for more exhaustive evaluation of their impact upon, and treatment of, disorders/neurotoxicity of the nigrostriatal dopaminergic system and the bases for the differences that exist between females and males.
Keywords: Body Weight, Body Temperature, GFAP, Bcl-2 PAI-1, IGF-1R, Dopamine Transporter, Body Weight, Body Temprature, Bcl-2 PAI, IGF-IR, Methamphetamine (MA), dihyroxyphenylacetic acid (DOPAC), Neurotoxicity, PAKT, GSK3 B, mRNA
Current Neuropharmacology
Title: Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity
Volume: 9 Issue: 1
Author(s): D. E. Dluzen, J. L. McDermott, M. Bourque, T. Di Paolo, A. S. Darvesh, A. B. Buletko and N. J. Laping
Affiliation:
Keywords: Body Weight, Body Temperature, GFAP, Bcl-2 PAI-1, IGF-1R, Dopamine Transporter, Body Weight, Body Temprature, Bcl-2 PAI, IGF-IR, Methamphetamine (MA), dihyroxyphenylacetic acid (DOPAC), Neurotoxicity, PAKT, GSK3 B, mRNA
Abstract: Three different approaches were employed to assess various markers associated with sex differences in responses to methamphetamine (MA). Bioassay measures reveal that MA treatment results in significantly greater reductions in body weight and increases in body temperature in male mice. Protein and mRNA determinations show significant increases in Bcl-2 and PAI-1 in male mice, while females show significant increases in GFAP and decreases in IGF-1R following treatment with MA. In mice with a heterozygous mutation of their dopamine transporter (+/- DAT), only female mice show significant differences in dopamine transporter binding and mRNA and associated reductions in striatal dopamine content along with increases in MA-evoked striatal dopamine output. The identification of these sex-dependent differences in markers provides a foundation for more exhaustive evaluation of their impact upon, and treatment of, disorders/neurotoxicity of the nigrostriatal dopaminergic system and the bases for the differences that exist between females and males.
Export Options
About this article
Cite this article as:
E. Dluzen D., L. McDermott J., Bourque M., Di Paolo T., S. Darvesh A., B. Buletko A. and J. Laping N., Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017399
DOI https://dx.doi.org/10.2174/157015911795017399 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Optic Nerve and Cerebral Edema in the Course of Diabetic Ketoacidosis
Current Neuropharmacology Editorial [Hot Topic: Prodrugs: Pharmaceutical Design and Current Perspectives (Executive Guest Editor: Josef Jampilek)]
Current Pharmaceutical Design Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Probiotics in the Prevention of Urogenital Tract Infections. Mechanisms Involved
Current Women`s Health Reviews Dopamine Pharmacological Agents in Resistant-OCD
Current Psychopharmacology Metabolomics and Pharmacological Screening of <i>Aspergillus versicolor</i> Isolated from <i>Hyrtios erectus</i> Red Sea Sponge; Egypt
Current Bioactive Compounds The Role of Advanced Technologies Supplemented with Traditional Methods in Pharmacovigilance Sciences
Recent Patents on Biotechnology Drug Delivery Systems Using Immobilized Intact Liposomes: A Comparative and Critical Review
Current Drug Delivery Neurobiological Basis and Pharmacologic Treatment of Social Impairment in Autism Spectrum Disorders
Current Psychopharmacology The Emerging Role of the Cannabinoid Receptor Family in Peripheral and Neuro-immune Interactions
Current Drug Targets When Ubiquitin Meets NF-κB: A Trove for Anti-cancer Drug Development
Current Pharmaceutical Design Targeting Transient Receptor Potential Canonical Channels for Diseases of the Nervous System
Current Drug Targets Antidepressant Desipramine Leads to C6 Glioma Cell Autophagy: Implication for the Adjuvant Therapy of Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases
Current Neuropharmacology The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Current Pharmaceutical Design Alzheimers Disease and Non-Steroidal Anti-Inflammatory Drugs: Old Therapeutic Tools with Novel Mechanisms of Action?
Current Medicinal Chemistry - Central Nervous System Agents Nitric Oxide and Dietary Factors: Part IV Traditional Japanese Food (Soy Products, Fish and Tea)
Vascular Disease Prevention (Discontinued) Tissue-Based Approaches to Study Pharmacodynamic Endpoints in Early Phase Oncology Clinical Trials
Current Drug Targets Muscle Dysfunction in Malnutrition
Current Nutrition & Food Science